Cheetah Medical said it added another $9 million to its coffers in a funding round led by Fletcher Spaght Ventures.
The Newton, Mass.-based medical device company, which makes a non-invasive hemodynamic monitoring system, said Springfield Investment Management, MVM Life Science Partners, Robert Bosch Venture Capital and Ascension Health Ventures also participated in the round.
The proceeds will be used to boost Cheetah Medical’s sales and marketing operations in the U.S. and overseas, president & CEO Chris Hutchison said in prepared remarks.
“Cheetah helps clinicians maintain appropriate hemodynamic balance in critically ill patients, avoiding the negative consequences associated with fluid overload, or inadequate perfusion,” Hutchison said.
Chris Walker contributed to this report.